Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Boston Scientific Corp (BSX)

Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 91,830,760
  • Shares Outstanding, K 1,486,175
  • Annual Sales, $ 20,074 M
  • Annual Income, $ 2,898 M
  • EBIT $ 4,509 M
  • EBITDA $ 5,923 M
  • 60-Month Beta 0.78
  • Price/Sales 4.54
  • Price/Cash Flow 15.19
  • Price/Book 3.72

Options Overview Details

View History
  • Implied Volatility 39.95% (+1.89%)
  • Historical Volatility 34.57%
  • IV Percentile 91%
  • IV Rank 69.70%
  • IV High 49.76% on 03/27/26
  • IV Low 17.38% on 07/29/25
  • Expected Move (DTE 4) 1.90 (3.07%)
  • Put/Call Vol Ratio 2.41
  • Today's Volume 27,736
  • Volume Avg (30-Day) 25,447
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 395,191
  • Open Int (30-Day) 402,208
  • Expected Range 59.89 to 63.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.80
  • Number of Estimates 9
  • High Estimate $0.86
  • Low Estimate $0.78
  • Prior Year $0.75
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.59 +1.98%
on 04/09/26
71.94 -14.11%
on 03/18/26
-8.17 (-11.68%)
since 03/10/26
3-Month
60.59 +1.98%
on 04/09/26
97.90 -36.88%
on 01/12/26
-35.85 (-36.72%)
since 01/09/26
52-Week
60.59 +1.98%
on 04/09/26
109.50 -43.57%
on 09/09/25
-30.85 (-33.30%)
since 04/10/25

Most Recent Stories

More News
Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , April 10, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against...

BSX : 61.79 (+0.83%)
BSX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options

BSX : 61.79 (+0.83%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines - BSX

NEW YORK , April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX).  ...

BSX : 61.79 (+0.83%)
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Penumbra , Inc....

BSX : 61.79 (+0.83%)
PEN : 329.77 (+0.08%)
BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit

NEW YORK , April 7, 2026 /PRNewswire/ -- 

BSX : 61.79 (+0.83%)
BSX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Boston Scientific Corporation Securities Lawsuit -- The Gross Law Firm

NEW YORK , April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Boston Scientific Corporation (NYSE: BSX).

BSX : 61.79 (+0.83%)
3 of Wall Street’s Favorite Stocks for Long-Term Investors

3 of Wall Street’s Favorite Stocks for Long-Term Investors

BSX : 61.79 (+0.83%)
G : 34.18 (-3.83%)
LDOS : 152.88 (-1.77%)
BSX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options

BSX : 61.79 (+0.83%)
Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , April 3, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

BSX : 61.79 (+0.83%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines - BSX

NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX).  ...

BSX : 61.79 (+0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and...

See More

Key Turning Points

3rd Resistance Point 63.06
2nd Resistance Point 62.42
1st Resistance Point 62.11
Last Price 61.79
1st Support Level 61.16
2nd Support Level 60.52
3rd Support Level 60.21

See More

52-Week High 109.50
Fibonacci 61.8% 90.82
Fibonacci 50% 85.04
Fibonacci 38.2% 79.27
Last Price 61.79
52-Week Low 60.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.